Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Directors' Dealings

24th Sep 2008 10:19

RNS Number : 1706E
ABCAM Plc
24 September 2008
 



For immediate release

24 September 2008

ABCAM PLC

("Abcam" or "the Company")

Directors' Dealings

Cambridge UK, 24 September 2008: Abcam plc announces that to meet demand from institutional investors the following transactions have been undertaken by Directors:

Director

Number of Shares Sold

Date sold

Price per Share Sold

(p)

Subsequent Beneficial Holding

Percentage of issued Share Capital following sale

David Cleevely

250,000

23 September 2008

480

3,319,760

9.46%

Jonathan Milner

1,000,000

23 September 2008

480

7,044,960

20.07%

Jim Warwick *

15,000

23 September 2008

480

853,200

2.43%

* 7,500 of these shares were sold by his wife Jane Dominey

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeff Iliffe, Chief Financial Officer

www.abcam.com

Numis Securities

+ 44 (0) 20 7776 1500

Nominated Adviser - Michael Meade, Nick Westlake

Corporate Broking - James Black

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Mary-Jane Johnson

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in CambridgeUK, with a US office located in CambridgeMassachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 45,000 products, most of which are antibodies, from over 200 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs 180 staff in its three operating companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSPUUQGBUPRUBC

Related Shares:

ABC.L
FTSE 100 Latest
Value8,809.74
Change53.53